
Erratum

Erratum to: Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop

Jane P. F. Bai,^{1,14} Robert Bell,² ShaAvhree Buckman,³ Gilbert J. Burckart,¹ Hans-Georg Eichler,⁴ Kenneth C. Fang,⁵ Federico M. Goodsaid,¹ William J. Jusko,⁶ Lawrence L. Lesko,¹ Bernd Meibohm,⁷ Scott D. Patterson,⁸ Oscar Puig,⁹ Jeffrey B. Smerage,¹⁰ Barbara J. Snider,¹¹ John A. Wagner,⁹ Jingsong Wang,^{12,13} Marc K. Walton,³ and Russell Weiner¹³

Published online 26 April 2011

Erratum to: The AAPS Journal
DOI: 10.1208/s12248-011-9265-x

Dr. Robert Becker of the FDA should have been acknowledged as having contributed materials on FDA regulations on diagnostic devices.

The online version of the original article can be found at <http://dx.doi.org/10.1208/s12248-011-9265-x>.

¹Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

²Drug & Biotechnology Development, LLC, Clearwater, Florida, USA.

³Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA.

⁴EMA, Canary Wharf, London, UK.

⁵XDx Expression Diagnostics, Brisbane, California, USA.

⁶University of Buffalo, State University of New York, Buffalo, New York, USA.

⁷University of Tennessee, Memphis, Tennessee, USA.

⁸Amgen Inc., Thousand Oaks, California, USA.

⁹Merck & Co, Inc, Rahway, New Jersey, USA.

¹⁰University of Michigan, Ann Arbor, Michigan, USA.

¹¹Washington University in St. Louis, St. Louis, Missouri, USA.

¹²Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

¹³Bristol Myers Squibb, Lawrenceville, New Jersey, USA.

¹⁴To whom correspondence should be addressed. (e-mail: jbai@fda.hhs.gov)